Logo Medical Science Monitor

Call: +1. 631. 470 VSports. 9640 Mon - Fri 10:00 am - 02:00 pm EST.

Contact Us

IF 2024: 2. 1 Log In Search Menu Journal's Content Current Volume In Press Archives Errates and Retraction Notes For Authors Instructions for Authors Documents / Forms Submit Manuscript Payments Journal's Information (V体育官网入口) Indexation Info Reviewers Editorial Board Editorial Office Advertising Policy Privacy Policy AI Policy Contact Us Log In Search (V体育平台登录) 01 January 2012: Clinical Research   VSports app下载.

Attentional and emotional functioning in schizophrenia patients treated with conventional and atypical antipsychotic drugs

Katarzyna Kucharska-Pietura ACDEFG , Aneta Tylec ABEFG , Andrzej Czernikiewicz DFG , Ann Mortimer CDE

DOI: 10.12659/MSM.882202

Med Sci Monit 2012; 18(1): CR44-49

0 Comments
Add Comment

"VSports在线直播" Background

“Atypical” antipsychotic drugs represent a second generation of antipsychotic drugs, with a significantly lower incidence of extrapyramidal side-effects (EPS) than “conventional” first generation antipsychotic drugs. Most atypical antipsychotic drugs possess a strong affinity for serotonin 5-HT2 receptors and relatively weak affinity for the dopamine D2 receptor [1]. Some clinical studies suggest that atypical antipsychotic drugs bring about improvement in cognitive symptoms, and that such improvement appears to be correlated with improvement of negative symptoms. This cognitive enhancement may be mediated by increases in dopamine and acetylcholine in prefrontal dorsolateral regions, and in those parts of the hippocampus associated with the acquisition and consolidation of new information [2–4] VSports手机版.

Several studies have evaluated the beneficial effect of atypical antipsychotic drugs on emotional and cognitive functions in schizophrenia [5–7].

Guilera et al. presented a meta-analysis of 18 independent studies (N=1808) with the aim of exploring whether patients treated with atypical antipsychotic drugs obtain better results on cognitive functioning than those treated with conventional antipsychotic drugs [8]. Their results showed a mild improvement in the global cognitive index of patients treated with atypical antipsychotic drugs. These minor benefits were observed particularly in speed of processing and learning tasks. These effects are somewhat lower than those found in the meta-analysis of Woodward et al V体育ios版. [7], who concluded that patients receiving atypical antipsychotic drugs performed moderately better on neuropsychological tests than those treated with conventional antipsychotic drugs.

By contrast, conventional antipsychotic drugs provide modest-to-moderate improvements in multiple cognitive domains [9]; specifically, some improvement in attention was recorded [10]. Moreover, treatment of EPS with anticholinergic drugs can impair memory. However, many of these studies comparing the effectiveness of conventional versus atypical antipsychotic drugs have been sponsored by the pharmaceutical industry, thus the effects of atypical antipsychotic drugs on cognitive and emotional function remain controversial [8] VSports最新版本.

Recent findings from CATIE (Clinical Antipsychotic Trials for Intervention Effectiveness), EUFEST (European First-Episode Schizophrenia Trial), CUTLASS (Cost Utility of the Latest Antipsychotic Drugs in Schizophrenia Study), TEOSS (Treatment of Early Onset Schizophrenia Spectrum Disorders) and other antipsychotic trials have suggested that neurocognitive improvements in patients treated with conventional or atypical antipsychotic drugs are minimal – neither class of drug is inferior to the other. Some benefit in patients with first-episode psychosis may be associated with symptom reduction, but most of the cognitive enhancement may have a practice effect, supplemented by the expectation of benefit [11–13] V体育平台登录.

Research on the influence of antipsychotic drug treatment on emotion recognition has produced inconsistent results VSports注册入口. Hempel et al. reviewed the effects of antipsychotic medication on facial affect recognition in schizophrenia according to 8 studies [14]. No substantial improvement was observed after treatment with either typical or atypical antipsychotic drugs. Facial affect recognition was not related to neuropsychological functioning, and it was unclear whether improvement of symptom severity was related to performance on facial affect recognition tasks. A growing body of evidence suggests that deficits in emotion perception are not significantly improved with atypical antipsychotic medication [15–18].

The aim of our study was to assess emotional and cognitive functioning in schizophrenia patients currently treated with conventional or atypical antipsychotic drugs.

The objectives of the study were:

Material and Methods

THE TEST OF EVERYDAY ATTENTION (TEA): The Test of Everyday Attention (TEA) is based on ecologically plausible activities such as searching maps, looking through telephone directories, and listening to lottery number broadcasts VSports在线直播. This test provides norm-referenced scores on tests that are sensitive to selective attention, sustained attention and attentional switching.

For study purposes, 3 subtests were used:

SHORT RECOGNITION MEMORY TEST FOR FACES (SRMT): This is a forced-choice recognition memory test. It consists of 25 unfamiliar grey-scale male faces, which are presented at a rate of 1 every 3 seconds (timed by stop watch). The subject is required to respond “yes” or “no” to each item, depending on whether the face is judged to be pleasant or not. Recognition memory is assessed immediately after the presentation of the stimuli using a 2-choice format, each stimulus item being paired with 1 distracter item. The number of correct choices for each subtest was recorded [24] V体育2025版.

FACIAL EXPRESSION RECOGNITION TEST (FERT):

Facial Expression Recognition Test (FERT) is a computerized task based on 25 facial expressions from a standardized series [25]. Subjects view prototypical facial expressions of the 6 basic emotions (fear, disgust, anger, surprise, happiness, sadness) and neutral facial expressions. They judge the emotion displayed by each facial expression.

“READING THE MIND IN THE EYES” TEST (“EYES TEST”):

“Reading the mind in the eyes” Test (“Eyes test”) is a measure of adult “metalizing”. It assesses how well the subject can put themselves into the mind of another person and empathies with their mental state. Subjects see 36 photographs of the eye region of unknown faces, and choose which of 2 words best describes what the person in the photo is thinking or feeling [26].

BALANCED EMOTIONAL EMPATHY SCALE (BEES):

The full-length (30 item) BEES was used. When completing the scale, subjects were asked to state the extent to which they agreed or disagreed with 30 statements (examples: Unhappy movie endings haunt me for hours afterward; I cannot feel much sorrow for those who are responsible for their own misery) using a 9-point agreement-disagreement scale [27].

ANALYSIS:

A repeated-measures analysis of variance was employed to determine the main effects of subject group and interactions between these factors. Post-hoc Tukey tests were then employed to examine specific differences in performance between groups. The influence of independent variables (eg, years of education) and mean Beck Depression Inventory (BDI) score on performance of experimental tasks was controlled by analyses of covariance (ANCOVAs). Finally, Pearson correlations were performed between mean accuracy scores and clinical variables (eg, SANS and SAPS score, BDI, antipsychotic dose, illness duration, and number of hospitalizations).

Results (V体育2025版)

PATIENTS VERSUS CONTROLS:

The Independent Samples T-test was used to compare test performance of patients versus controls – controls outperformed patients to a highly statistically significant degree (p<0.001) in all tests.

Analysis of variance (ANOVA) indicated that the 3 groups differed significantly in years of education (F=8.02; df=2.147; p<0.001) and severity of depressive symptoms on Beck Depression Inventory (BDI) (F=29.07; df=2.147; p<0.001).

Post-hoc Tukey multiple comparison procedures failed to find statistically significant differences in test performance between the 2 patient groups: (TEA Sc/Sa mean difference =1.14; p=0.43; SRMT Sc/Sa mean difference =0.36; p=0.82; FERT Sc/Sa mean difference =0.91; p=0.48; Eyes test Sc/Sa mean difference =2.27; p=0.89; BEES Sc/Sa mean difference =4.83; p=0.59).

Apparently data analysis in our sample might suggest prescribing bias.

Our patients treated on atypical antipsychotic drugs appeared to be less severely ill (lower mean scores on both SANS and SAPS) and less depressed (lower mean BDI score). Furthermore, they were younger and presented with lower numbers of admissions and shorter illness duration. They outperformed the conventional treated patients on every test. Despite their clinical and demographic advantages, the better performance of atypical antipsychotic treated patients was not statistically superior to the performance of patients treated with conventional antipsychotics.

RELATIONSHIP BETWEEN EMOTIONAL PERCEPTION AND INDEPENDENT VARIABLES:

The influence of education, mood (mean BDI score) and neutral perceptual control task score (SRMT) on emotional perception was evaluated using ANCOVA. The only significant covariate was neutral task performance. However, when this was taken into account the effect of group on performance remained highly significant (Table 2).

Analysis of Pearson correlations in patients on both conventional and atypical antipsychotics showed statistically significant correlations between mean FERT score and mean scores on the SAPS (Sc r=−0.45; p=0.004; Sa r=−0.27; p=0.03), SANS (Sc r=−0.62; p=0.001; Sa r=−0.32; p=0.01), number of admissions (Sc r=−0.66; p=0.001; Sa r=−0.37; p=0.003), illness duration (Sc r=−0.59; p=0.001; Sa r=−0.37; p=0.003), and subject age (Sc r=−0.67; p=0.001; Sa r=−0.38; p=0.002).

Regarding the “Reading the mind in the eyes” test in schizophrenia patients on conventional antipsychotic drugs, Pearson correlations analyses showed statistically significant correlations between score and frequency of admissions (r=−0.40; p=0.01), illness duration (r=−0.48; p=0.002) and age (r=−0.38; p=0.016). In the patient group on atypical antipsychotic drugs no significant correlations were found.

BEES:

Analysis of covariance (mean score as dependent variable), the type of antipsychotic FGA or SGA as a fixed factor were carried out, with years of education and mean score of BDI as covariates. The effect of group upon performance on this test remained highly significant (F=5.40; df=2.148; P=0.005) after controlling for these covariates.

Pearson correlations analyses showed statistically significant correlations between mean test score and mean SANS score (r=−0.27; P=0.036) in patients treated with atypical antipsychotic drugs.

SRMT:

The effect of group upon performance on SRMT did not remain significant (F=1.56; df=2.148; P=0.21) after controlling for years of education and mean score of BDI as covariates. The analysis showed that both covariates appeared significant (education F=4.37; df=1; P=0.04; BDI F=9.52; df=1; P=0.002).

TEA:

The effect of group upon performance on TEA remained highly significant (F=47.28; df=2.147; P=0.001) after controlling for years of education and mean score of BDI as covariates. Again, both covariates were significant (education F=4.19; df=1; P=0.04; BDI F=7.13; df=1; P=0.008).

Analyses of Pearson correlations in the patient group treated using conventional antipsychotics revealed statistically significant correlations between mean TEA score and mean scores of SAPS (r=−0.51; p=0.004), SANS r=−0.45; p=0.001), and numbers of admissions r=−0.31; p=0.001), illness duration (r=−0.50; p=0.001), as well as age of examined subjects r=−0.58; p=0.001). In the patient group treated using atypical antipsychotic drugs, analysis of Pearson correlations showed statistically significant correlations between mean TEA score and numbers of admissions (r=−0.31; p=0.014) and illness duration (r=−0.32; p=0.012).

Discussion

Our results show significant differences between patients and healthy controls in all tasks (apart from the Short Recognition Memory Test for Faces) after controlling for covariates, with schizophrenia patients performing worse than controls.

Schizophrenia patients have difficulty in recognizing emotions, empathizing with others and “putting themselves into someone else shoes” (theory of mind), and demonstrate deficits in understanding social instructions [28–31]. It has been argued that conventional antipsychotic drugs possess the capacity to restore emotional and cognitive deficits in schizophrenia [5,7,10,32].

ANCOVA results in this study did not show significant impairment in processing facial information per se in schizophrenia patients; however, they confirmed the presence of deficits in perception of emotions in schizophrenia. Moreover, other significantly deeper deficits were shown in the scope of reading “the state of mind” of other people (theory of mind) and at the emotional empathy level in schizophrenia patients, in comparison with the group of healthy controls. Furthermore, the schizophrenia patients demonstrated deficits in attention function, in particular selective and sustained attention and switching attention.

The results of this study confirmed neither the positive effect of atypical antipsychotics nor the negative influence of conventional antipsychotic drugs on emotional and attentional functions in schizophrenia. Thus, the type of the antipsychotic drug used in the study (typical versus atypical) seems not to have a substantial effect on improvement or deterioration in emotional and cognitive domains. The emotional and attentional deficits remained dependent on the evaluated variables, particularly on exacerbation of illness symptoms, number of hospitalizations, illness duration and on the age of the people examined (ie, general severity effects).

The results of our study are in agreement with those of Selva-Vera et al. [33], who found no greater cognitive enhancement over 2 years in patients taking atypical antipsychotic drugs, compared to those treated with conventional antipsychotic drugs.

Interestingly, recent prominent studies assessing the effect of antipsychotic drugs on restoring emotional functioning in schizophrenia have shown no statistically significant improvement [14,15,17,18], which agrees with the results of our study.

However, the cross-sectional design of our study allowed us to conduct only one-time evaluation of emotional and attentional functioning. Prospective, randomized comparison trials of well matched patients would be necessary to settle the issue. To date it seems that most of the evidence points in the same direction, in that it is not possible to demonstrate cognitive or attentional advantages for patients treated with atypical antipsychotic drugs. This is the case even when controlling for prescribing biases. Finally, these results are consistent with those from large randomized pragmatic trials, which have repeatedly demonstrated that (with the exception of EPSE for most exemplars) the claimed advantages for atypical antipsychotic drugs are more apparent than real.

VSports - References

1. Kapur S, Remington G, Atypical antipsychotic drugs: New Directions and New Challenges in the Treatment of Schizophrenia: Canadian Journal of Psychiatry, 2001; 42; 265-73

2. Ichikawa J, Ishii H, Bonaccorso S, 5-HT(2A) and D(2) receptor blockade increases cortical DA release via 5-HT(1A) receptor activation: A possible mechanism of atypical antipsychotic-induced cortical dopamine release: J Neurochem, 2001; 76; 1521-31, pmid: 11238736

3. Stip E, Chouinard S, Boulay LJ, On the trail of a cognitive enhancer for the treatment of schizophrenia: Prog Neuro-Psychopharmacology & Biological Psychiatry, 2005; 29; 219-32

4. Vakalopoulos C, A new nosology of psychosis and the pharmacological basis of affective and negative symptom dimensions in schizophrenia: Mental Illness, 2010; 2; 28-38

5. Behere RV, Venkatasubramanian G, Arasappa R, Effect of risperidone on emotion recognition deficits in antipsychotic-naïve schizophrenia: a short-term follow-up study: Schizophrenia Research, 2009; 113; 72-76, pmid: 19545977

6. Littrell KH, Petty RG, Hilligoss NM, Valproate for hostility in schizophrenia patients: J Clin Psychiatry, 2004; 65; 134, pmid: 14974493

7. Woodward ND, Purdon SE, Meltzer HY, Zald DH, A meta-analysis of neuropsychological change to clozapine, olanzapine, quetiapine, and risperidone in schizophrenia: Int J Neuropsychopharmacol, 2005; 8; 457-72, pmid: 15784157

8. Guilera G, Pino O, Gómez-Benito J, Rojo JE, Antipsychotic effects on cognition in schizophrenia: A meta-analysis of randomised controlled trials: European Journal of Psychiatry, 2009; 23; 77-89

9. Mishara AL, Goldberg TE, A meta-analysis and critical review of the effects of conventional neuroleptic treatment on cognition in schizophrenia: opening a closed book: Biol Psychiatry, 2004; 55; 1013-22, pmid: 15121486

10. King DJ, The effect of neuroleptics on cognitive and psychomotor function: Br J Psychiatry, 1990; 157; 799-811, pmid: 1981157

11. Goldberg TE, Goldman RS, Burdick KE, Cognitive improvement after treatment with second-generation antipsychotic medications in first-episode schizophrenia: Is it a practice effect?: Arch Gen Psychiatry, 2007; 64; 1115-22, pmid: 17909123

12. Keefe RE, Bilder RM, Davis SMfor the CATIE Investigators and the Neurocognitive Working Group, Neurocognitive effects of antipsychotic medications in patients with chronic schizophrenia in the CATIE trial: Arch Gen Psychiatry, 2007; 64; 633-47, pmid: 17548746

13. Schwartz MS, Perkins DO, Stroup TS, Effects of antipsychotic medications on psychosocial functioning in patients with chronic schizophrenia: findings from NIMH CATIE study: Am J Psychiatry, 2007; 164; 428-36, pmid: 17329467

14. Hempel RJ, Dekker JA, Van Beveren NJ, The effect of antipsychotic medication on facial affect recognition in schizophrenia: A review: Psychiatry Res, 2010; 178; 1-9, pmid: 20452051

15. Herbener ES, Hill K, Marvin RW, Sweeney JA, Effects of Antipsychotic Treatment on Emotion Perception Deficits in First-Episode Schizophrenia: Am J Psychiatry, 2005; 162; 1746-48, pmid: 16135639

16. Lewis SF, Garver DL, Treatment and diagnostic subtype in facial recognition in schizophrenia: J Psychiatr Res, 1995; 29; 5-11, pmid: 7629755

17. Penn DL, Keefe RS, Davis SM, The effects of antipsychotic medications on emotion perception in patients with chronic schizophrenia in the CATIE trial: Schizophr Res, 2009; 115; 17-23, pmid: 19766459

18. Sergi MJ, Green MF, Widmark C, Social cognition [corrected] and neurocognition: effects of risperidone, olanzapine, and haloperidol: Am J Psychiatry, 2007; 164; 1585-92, pmid: 17898351

19. American Psychiatric Association: Diagnostic and Statistical Manual of Mental Disorders (DSM-IV), 1994, Washington

20. Andreasen N: The scale for assessment of negative symptoms (SANS) The scale for assessment of positive symptoms (SAPS), 1984, Iowa City, University of Iowa

21. Beck A, Ward C, Mendelson M, An inventory for measuring depression: Arch Gen Psychiatry, 1961; 4; 561-71, pmid: 13688369

22. Annett M, Classification of hand preference by association analysis: Br J Psychol, 1970; 36; 303-21, pmid: 5457503

23. Robertson IH, Ward T, Ridgeway V, Nimmo-Smith I: The Test of Everyday Attention, 1994, Cambridge, Thames Valley Test Company

24. Warrington EK: The Camden Memory Tests Manual, 1996, East Sussex, Psychology Press, Taylor & Francis Ltd

25. Ekman P, Friesen WV: Facial Acting Coding System, 1978, Consulting Psychologists Press

26. Baron-Cohen S, Wheelwright S, Hill J, The ‘Reading the mind in the eyes’ test revised version: a study with normal adults, and adults with Asperger Syndrome or high-functioning autism: J Child Psychol Psychiatry, 2001; 42; 241-52, pmid: 11280420

27. Mehrabian A: Manual for the Balanced Emotional Empathy Scale (BEES), 2000, 1130 Alta Mesa Road, Monterey, CA 93940, Albert Mehrabian

28. Bigelow N, Paardiso S, Adolphs R, Perception of social stimuli in schizophrenia: Schizophrenia Research, 2006; 83; 257-67, pmid: 16497483

29. Brüne M, Emotion recognition, ‘theory of mind’, and social behaviour in schizophrenia: Psychiatry Research, 2005; 133; 135-47, pmid: 15740990

30. Kucharska-Pietura K, David AS, Masiak M, Phillips ML, Perception of facial and vocal affect by people with schizophrenia in early and late stages of illness: Br J Psychiatry, 2005; 187; 523-28, pmid: 16319404

31. Trémeau F, Emotion deficits in schizophrenia: Dialogues Clin Neurosci, 2006; 8; 58-68

32. Wysokiński A, Zboralski K, Orzechowska A, Normalization of the Verbal Fluency Test on the basis of results for healthy subjects, patients with schizophrenia, patients with organic lesions of the chronic nervous system and patients with type 1 and 2 diabetes: Arch Med Sci, 2010; 6(3); 438-46, pmid: 22371783

33. Selva-Vera G, Balanzá-Martínez V, Salazar-Fraile J, The switch from conventional to atypical antipsychotic treatment should not be based exclusively on the presence of cognitive deficits. A pilot study in individuals with schizophrenia: BMC Psychiatry, 2010; 10; 47, pmid: 20550658

In Press

VSports在线直播 - Clinical Research  

Dexmedetomidine Dose-Dependent Modulation of Lung Function and AQP1 Expression During One-Lung Ventilation ...

Med Sci Monit In Press; DOI: 10.12659/MSM.949221  

"VSports注册入口" Clinical Research  

A 3D-Printed Transoral Guide Device to Aid Single-Person Fiberoptic Intubation: A Randomized Clinical Trial

Med Sci Monit In Press; DOI: 10.12659/MSM.950276  

Clinical Research  

Epidemiology of Norovirus Outbreaks in Kindergartens, Primary Schools, and Junior High Schools in Xi'an, Ch... (VSports app下载)

Med Sci Monit In Press; DOI: 10.12659/MSM.949902  

Database Analysis  

Acute Kidney Injury Among Patients Undergoing Orthopedic Surgery and Admitted to the ICU: A Retrospective A...

Med Sci Monit In Press; DOI: 10.12659/MSM.950802  

Most Viewed Current Articles

17 Jan 2024 : Review article   10,154,418

Vaccination Guidelines for Pregnant Women: Addressing COVID-19 and the Omicron Variant

DOI :10.12659/MSM.942799

Med Sci Monit 2024; 30:e942799

0:00

13 Nov 2021 : Clinical Research   3,681,888

Acceptance of COVID-19 Vaccination and Its Associated Factors Among Cancer Patients Attending the Oncology ...

DOI :10.12659/MSM.932788

Med Sci Monit 2021; 27:e932788

0:00

14 Dec 2022 : Clinical Research   2,332,890

Prevalence and Variability of Allergen-Specific Immunoglobulin E in Patients with Elevated Tryptase Levels (V体育官网)

DOI :10.12659/MSM.937990

Med Sci Monit 2022; 28:e937990

0:00

16 May 2023 : Clinical Research   705,513

Electrophysiological Testing for an Auditory Processing Disorder and Reading Performance in 54 School Stude...

DOI :10.12659/MSM.940387

Med Sci Monit 2023; 29:e940387

0:00

Your Privacy

We use cookies to ensure the functionality of our website, to personalize content and advertising, to provide social media features, and to analyze our traffic. If you allow us to do so, we also inform our social media, advertising and analysis partners about your use of our website, You can decise for yourself which categories you you want to deny or allow. Please note that based on your settings not all functionalities of the site are available. View our privacy policy.

Medical Science Monitor eISSN: 1643-3750
Medical Science Monitor eISSN: 1643-3750